NBIX

Neurocrine Biosciencesdistress 0/10 · well-funded / low risk

$170.63-1%today-5% from 52w high

neurocrine.com2,000 employeesFounded 1992San Diego, CADrug Manufacturers - Specialty & Generic

Neurology 1Psychiatry / CNS 1

Lead: Schizophrenia · est. market ~$8B (approx, global)

Revenue

$815M

Liquidity

$936M

Runway

—

Shares 1y

+1%

Price & events

+24.2% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.2%

-0.5%

+5.7%

+31.1%

+25.3%

+27.7%

+17.3%

+73.2%

+78.0%

All

Overview

Market Cap: $17.16B
Volume: 37.96K
52 Week Range: $123 – $181
Total Shares: 100.55M
Float Shares: 99.30M
Short %: 7.17%
% Held by Insiders: 1.08%
% Held by Institutions: 104.07%
RVOL: 0.03x
Beta: 0.39

Pipeline stages · 3 programs

NBI-1117568

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-02

Crinecerfont

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-03

Valbenazine

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-04

Pipeline · 17 trials · 15 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-02 Estimated 50% readout ~2027-03-18	Phase 2	NBI-1065890	Tardive Dyskinesia	—	recruiting
2027-07 Estimated 50% readout ~2027-09-14	Phase 3	NBI-1065845	Major Depressive Disorder	—	recruiting
2027-07 Estimated 50% readout ~2027-09-14	Phase 3	NBI-1065845	Major Depressive Disorder	—	recruiting
2027-07 Estimated 50% readout ~2027-09-14	Phase 3	NBI-1065845	Major Depressive Disorder	—	recruiting
2027-08 Estimated 50% readout ~2027-09-15	Phase 2	NBI-1117570	Schizophrenia	—	recruiting

Show all 17 trials · 12 more ▾

Readout	Phase	Drug	Indication	Enroll	Status
2027-10 Estimated 50% readout ~2027-12-15	Phase 3	NBI-1117568	Schizophrenia	—	recruiting
2027-11 Estimated 50% readout ~2028-01-15	Phase 3	NBI-1117568	Schizophrenia	—	recruiting
2028-02 Estimated 50% readout ~2028-03-17	Phase 2	NBI-1117568	Bipolar I Disorder, Mania	—	recruiting
2028-03 Estimated 50% readout ~2028-04-15	Phase 2	Crinecerfont	Congenital Adrenal Hyperplasia	—	not yet recruiting
2028-04 Estimated 50% readout ~2028-06-15	Phase 3	Valbenazine	Chorea, Huntington	—	enrolling by invitation
2028-07 Estimated 50% readout ~2028-09-14	Phase 3	NBI-1065845	Major Depressive Disorder	—	recruiting
2029-05 Estimated 50% readout ~2029-07-15	Phase 3	NBI-1065845	Major Depressive Disorder	—	recruiting
2029-07 Estimated 50% readout ~2029-09-14	Phase 3	NBI-1117568	Schizophrenia	—	recruiting
2029-09-06 Estimated 50% readout ~2029-10-21	Phase 2	Crinecerfont	Congenital Adrenal Hyperplasia	—	active not recruiting
2031-12 Estimated 50% readout ~2032-02-14	Phase 3	NBI-1117568	Schizophrenia	—	recruiting
2025-11-12	Phase 2	NBI-921352	SCN8A Developmental and Epileptic Encephalopathy Syndrome	8	terminated
2025-02-04	Phase 3	Placebo, Valbenazine	Schizophrenia	442	completed